GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Price-to-Free-Cash-Flow

Arovella Therapeutics (ASX:ALA) Price-to-Free-Cash-Flow : N/A (As of Apr. 29, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-29), Arovella Therapeutics's share price is A$0.12. Arovella Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01. Hence, Arovella Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Arovella Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

ASX:ALA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.135
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Arovella Therapeutics's Free Cash Flow per Share for the six months ended in Dec. 2023 was A$-0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was A$-0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 22.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 29.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 21.80% per year.

During the past 13 years, Arovella Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 69.30% per year. The lowest was -190.20% per year. And the median was 14.60% per year.


Arovella Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Arovella Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Price-to-Free-Cash-Flow Chart

Arovella Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arovella Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arovella Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Arovella Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arovella Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Price-to-Free-Cash-Flow falls into.



Arovella Therapeutics Price-to-Free-Cash-Flow Calculation

Arovella Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.12/-0.008
=N/A

Arovella Therapeutics's Share Price of today is A$0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arovella Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Arovella Therapeutics  (ASX:ALA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Arovella Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Arovella Therapeutics (ASX:ALA) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (ASX:ALA) Headlines

No Headlines